Blocking CXCR4 in combination with anti–PD–1 therapy enhances antigen presentation and increases cDC1 infiltration into tumors, as demonstrated in orthotopic and autochthonous hepatocellular carcinoma (HCC) models [69]. Here, CXCR4 is linked to hepatocellular carcinoma.